11 completed, 1 enrolling by invitation, 1 unknown. 13 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 11, Enrolling by invitation 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow Ceftaroline: new trials by email Literature Review of Ceftaroline trials Research Report on Ceftaroline
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection Mycobacteriophage Muddy_HRMN0052, Amikacin Injection, Clofazimine - Non-Tuberculous Mycobacterial (NTM) Pneumonia, Mycobacterium Abscessus Infection | Phase 1 | Enrolling by invitation | Vancouver Coastal Health | 1 | 2026-01-11 | 2026-06-03 |
| Population Pharmacokinetic (PK) Study of Zinforo (Ceftaroline) in Critical Care Patients With Early-onset Pneumonia and Normal or Augmented Renal Clearance Ceftaroline - Pneumonia | Phase 1 | Completed | Poitiers University Hospital | 18 | 2016-12-01 | 2019-03-11 |
| Ceftaroline Diffusion Into Cerebrospinal Fluid of Children Ceftaroline - Cerebrospinal Fluid Shunts, Ventriculoperitoneal Shunt | Phase 1 | Unknown | Basim Asmar | 12 | 2016-08-01 | 2018-10-04 |
| Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children Ceftaroline Fosamil - Hematogenously Acquired Staphylococcus Aureus Osteomyelitis, Bone Infection | Phase 1 / Phase 2 | Completed | Baylor College of Medicine | 11 | 2015-06-03 | 2021-11-02 |
| Penetration of Ceftaroline Into Cerebrospinal Fluid(CSF) Ceftaroline fosamil - Meningitis, Ventriculitis | Phase 1 | Completed | Centre Hospitalier Universitaire Dijon | 10 | 2015-04-29 | 2024-02-21 |
| A Study to Assess the Pharmacokinetics of Ceftaroline in End Stage Renal Disease Patients and Matched Healthy Subjects 200 mg Ceftaroline fosamil, 600 mg Ceftaroline fosamil - Renal Disease | Phase 1 | Completed | Pfizer | 15 | 2013-02-01 | 2017-09-05 |
| A Study to Assess Safety, Tolerability and Pharmacokinetics of Ceftaroline in Healthy Subjects 600 mg Ceftaroline fosamil, Placebo - Healthy Volunteers | Phase 1 | Completed | Pfizer | 41 | 2012-07-01 | 2017-09-05 |
| Pharmacokinetics of Ceftaroline in Normal and Obese Subjects Ceftaroline - Drug Safety | Phase 1 | Completed | Keith A. Rodvold | 32 | 2012-07-01 | 2013-03-14 |
| Pharmacokinetic Study of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance Ceftaroline fosamil/Avibactam (CXL) - Augmented Renal Clearance (ARC), Systemic Inflammatory Response Syndrome (SIRS) | Phase 1 | Completed | Forest Laboratories | 12 | 2012-05-01 | 2017-04-07 |
| A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects 600 mg ceftaroline fosamil in 50 ml infusion volume, Placebo in 50 ml infusion volume, 600 ceftaroline fosamil in 250 ml infusion volume - Healthy | Phase 1 | Completed | Pfizer | 34 | 2012-04-01 | 2017-09-05 |
| Ceftaroline China Pharmacokinetics Study Ceftaroline - Healthy | Phase 1 | Completed | Pfizer | 24 | 2011-10-01 | 2017-09-05 |
| A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers NXL104, Ceftaroline, Placebo Infusion - Healthy Male Volunteers | Phase 1 | Completed | Pfizer | 54 | 2011-02-01 | 2017-09-01 |
| Pharmacokinetics of Ceftaroline in Subjects 12 to 17 Years of Age ceftaroline - Infection | Phase 1 | Completed | Forest Laboratories | 9 | 2008-03-01 | 2017-03-14 |
Pneumonia (2) · Infections (1) · Kidney Diseases (1) · Lung Diseases (1) · Meningitis (1) · Mycobacterium Infections, Nontuberculous (1) · Obesity (1) · Osteomyelitis (1) · Systemic Inflammatory Response Syndrome (1)
Pfizer (5) · Forest Laboratories (2) · Basim Asmar (1) · Baylor College of Medicine (1) · Centre Hospitalier Universitaire Dijon (1) · Keith A. Rodvold (1) · Poitiers University Hospital (1) · Vancouver Coastal Health (1)
United States (6) · United Kingdom (3) · France (2) · Australia (1) · Canada (1) · China (1)
David Melnick, MD (3) · Mirjana Kujacic, MD (3) · Elizabeth Tranter, MBCHB MRCP (2) · Arpeat Kaviya, MBChB, MRCP (1) · David Mathews, MD (1) · David Melnick (1) · Keith A Rodvold, Pharm.D. (1) · Paul Newell, MD (1) · Sheldon L. Kaplan, MD (1)
PMID 30380060, PMID 26152131, PMID 24150927, PMID 25041494, PMID 25896707, PMID 30221827, PMID 30535190, PMID 31044546, PMID 36059138